Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.009
Sell
RSI(14)
37.572
Neutral
STOCH(KDJ)(9,3,3)
33.872
Sell
ATR(14)
0.217
Low Volatility
CCI(14)
-165.473
Sell
Williams %R
96.296
Oversold
TRIX(12,20)
-0.344
Sell
StochRSI(14)
0.000
Sell
Search
Orchestra Biomed Holdings Inc
OBIOAdd to Watchlist
3.720USD
-0.390-9.49%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
222.76MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Orchestra Biomed Holdings Inc
Currency: USD Updated: 2026-05-15Key Insights
Orchestra Biomed Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 122 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.57.In the medium term, the stock price is expected to remain stable.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Orchestra Biomed Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Orchestra Biomed Holdings Inc Highlights
StrengthsRisks
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1113.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.48M.
Fairly Valued
The company’s latest PE is -3.92, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.76M shares, increasing 8.04% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 151.30K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
12.571
Target Price
+205.87%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Orchestra Biomed Holdings Inc is 5.65, ranking 192 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 110.00K, representing a year-over-year decrease of 87.33%, while its net profit experienced a year-over-year decrease of 10.14%.
Score
Financials
7.30
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.15
Operational Efficiency
2.84
Growth Potential
3.88
Shareholder Returns
7.08
Orchestra Biomed Holdings Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Orchestra Biomed Holdings Inc is 8.38, ranking 23 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -3.92, which is -67.27% below the recent high of -1.28 and -321.57% above the recent low of -16.54.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 122/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Orchestra Biomed Holdings Inc is 8.00, ranking 66 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 12.00, with a high of 20.00 and a low of 10.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
12.571
Target Price
+205.87%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
93
Total
4
Median
7
Average
Company name
Ratings
Analysts
Orchestra Biomed Holdings Inc
OBIO
8
Boston Scientific Corp
BSX
37
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
35
Veeva Systems Inc
VEEV
30
Thermo Fisher Scientific Inc
TMO
30
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Orchestra Biomed Holdings Inc is 5.39, ranking 175 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 4.38 and the support level at 3.38, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.972
Sell
MA10
3.997
Sell
MA20
4.040
Sell
MA50
4.276
Sell
MA100
4.225
Sell
MA200
3.815
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Orchestra Biomed Holdings Inc is 3.00, ranking 133 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 42.19%, representing a quarter-over-quarter increase of 7.86%. The largest institutional shareholder is PRFDX, holding a total of 364.64K shares, representing 0.61% of shares outstanding, with 47.07% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Orchestra Biomed Holdings Inc is 2.78, ranking 145 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.49
VaR
+7.67%
240-Day Maximum Drawdown
+34.77%
240-Day Volatility
+75.10%
Return
Best Daily Return
60 days
+8.33%
120 days
+15.19%
5 years
+58.09%
Worst Daily Return
60 days
-9.49%
120 days
-9.49%
5 years
-24.30%
Sharpe Ratio
60 days
-0.30
120 days
-0.41
5 years
+0.20
Risk Assessment
Maximum Drawdown
240 days
+34.77%
3 years
+78.18%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+0.51
3 years
-0.19
5 years
-0.12
Skewness
240 days
+0.34
3 years
+1.05
5 years
+1.82
Volatility
Realised Volatility
240 days
+75.10%
5 years
--
Standardised True Range
240 days
+6.88%
5 years
+23.93%
Downside Risk-Adjusted Return
120 days
-76.82%
240 days
-76.82%
Maximum Daily Upside Volatility
60 days
+35.43%
Maximum Daily Downside Volatility
60 days
+37.60%
Liquidity
Average Turnover Rate
60 days
+0.56%
120 days
+0.56%
5 years
--
Turnover Deviation
20 days
+3.57%
60 days
-5.55%
120 days
-5.24%
Peer Comparison
Healthcare Equipment & Supplies
Orchestra Biomed Holdings Inc
OBIO
5.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
BRKR
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
